MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
As of 25 April 2024, 33 patients were enrolled, 19 patients were randomized, 14 patients completed the study.
- As of 25 April 2024, 33 patients were enrolled, 19 patients were randomized, 14 patients completed the study.
- Three subjects reported serious adverse events (SAE) and were all considered “Unlikely related” or “Unrelated“ to study drug.
- Objectives of this study are to evaluate the effects of MN-001 and its major active metabolite MN-002 on cholesterol efflux capacity in THP-1 *1macrophages.
- ABCG1 also effluxes cholesterol to low-density lipoproteins (LDL), liposomes and cyclodextrin and it exports sphingomyelin, phosphatidylcholine and oxysterols to HDL and albumin.